AzTrials
AzTrials

HIV InfectionsG2ZNCT03895619

Getting to Zero: Safer Conception Programming Among HIV Sero-different Couples in Uganda

A study testing Safer conception strategies in people with HIV Infections, run by Simon Fraser University at 1 site in Uganda.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Despite effective strategies to reduce periconception HIV transmission, there are few services to support people living with or affected by HIV to use these methods. In particular, there is a lack of safer conception services focused on engaging men living with HIV. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
HIV Infections
What is being tested?
Safer conception strategies
Could I receive a placebo?
No, everyone receives an active treatment
How many people
47 participants
Where
1 siteUganda
Study dates
26 Nov 2018to 31 Oct 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • For enrollment in the Getting to Zero study, eligibility criteria for the index participant include the following:
  • Identify as male
  • HIV-positive
  • Report personal or partner desire to have a child in the next year
  • Identified pregnancy partner is reported to be HIV-negative or he doesn't know her HIV serostatus.
  • Aged 18 years or older.
Show all 14Show fewer
  • Be naïve to the Healthy Families program.
  • Live within 60km of the ISS clinic and not planning to relocate to an area incompatible with an ability to attend the clinic over a 1 year follow-up period.
  • Able and willing to participate in the informed consent process.
  • Men living with HIV enrolled in the Getting to Zero study (index participants) will be asked for their consent to contact their partners to determine eligibility, interest, and willingness to participate in the Getting to Zero study. Partner participants must meet the following inclusion criteria:
  • Identify as a partner of an enrolled male Getting to Zero participant
  • Aged 18 years or older
  • Able and willing to participate in the informed consent process.
  • These participants will be referred to as the "partner". If the female partner is identified as HIV-positive after the male index participant enrolls in the Getting to Zero study, both partners remain eligible to participate.

Who cannot join

  • Identify as female
  • HIV-negative
  • Does not report personal or partner desire to have a child in the next year
  • Identified pregnancy partner is reported to be HIV-positive
  • Under age 18 years.
  • Be a patient of the Healthy Families program.
  • Live greater than 60km of the ISS clinic and planning to relocate to an area incompatible with attending the clinic over a 1 year follow-up period.
  • Unable and unwilling to participate in the informed consent process.

Trial locations and contacts

1 site in 1 country.

Uganda1 site
  • Immune Suppression Syndrome (ISS) Clinic at the Mbarara Regional Referral Hospital (MRRH)

    Mbarara

Other trials in Uganda

About this study

Official title: Getting to Zero: Safer Conception Programming to Eliminate Sexual and Perinatal HIV Transmission Among HIV Sero-different Couples in Uganda

Despite effective strategies to reduce periconception HIV transmission, there are few services to support people living with or affected by HIV to use these methods. In particular, there is a lack of safer conception services focused on engaging men living with HIV. Given known gender inequities in childbearing decision-making and HIV risk, it is critical that safer conception services deliver programming that engages men living with HIV and their HIV sero-different partners. The Healthy Families program, based at the ISS Clinic at Mbarara Regional Referral Hospital, offers client-centered safer conception care to help HIV-affected individuals and couples meet reproductive goals. This care supports clients to leverage personal motivations and partner and social supports to overcome structural barriers and use Antiretroviral Therapy (ART), adopt other HIV-prevention strategies, and remain in care. This pilot study (the 'Getting to Zero' study) will assess uptake and experiences of safer conception care among 50 men living with HIV and their HIV sero-different partners. Investigators will also assess men's retention in HIV care and HIV transmission risk to partners and infants. This is a one-year mixed-methods prospective pilot research study, which will use electronic chart review data, longitudinal survey data (from the male index and female partner participant), and qualitative data from in-depth semi-structured interviews to meet study objectives. By demonstrating safer conception uptake and impact on HIV transmission risks to partners and infants, investigators aim to inform HIV and reproductive health policy in Uganda and globally.

Read the detailed description

The Healthy Families safer conception program, based at the ISS Clinic at Mbarara Regional Referral Hospital (MRRH), offers client-centered care to help HIV-affected individuals and couples meet reproductive goals. This care supports clients to leverage personal motivations and partner and social supports to overcome structural barriers and use ART, adopt other HIV-prevention strategies, and remain in care. This pilot study (the 'Getting to Zero' study) will assess uptake and experiences of safer conception care among men living with HIV and their HIV sero-different partners, and will assess retention in care and HIV transmission risk to partners and infants.

There are six linked objectives in this study:

  1. To assess uptake of safer conception strategies among men living with HIV and/or their female partners overall, and by specific HIV prevention strategies. Hypothesis 1: Investigators hypothesize that offering comprehensive safer conception services within HIV care will increase uptake of HIV prevention strategies among both male and female HIV-affected participants (including ART initiation, adherence, and HIV-RNA viral suppression in the partner living with HIV, HIV-serostatus disclosure, knowledge of partner's HIV-serostatus, Sexually Transmitted Infections (STI) testing and treatment, sexual behaviour (i.e., delaying condomless sex until HIV-infected partner is virally suppressed), and partner HIV testing and ARV use (PrEP or ART).
  2. Among men living with HIV and their partners, to assess socio-demographic, relationship, structural, and clinical factors associated with uptake of safer conception strategies. Hypothesis 2: Investigators hypothesize that uptake will be associated with more equitable relationship power and dynamics, lower HIV-related stigma, higher social support, and other socio-structural determinants of health.
  3. To assess retention in HIV care among men living with HIV engaged in the safer conception intervention. Hypothesis 3: Investigators hypothesize that men living with HIV who are engaged in the safer conception intervention will be better retained in HIV care over nine months relative to men receiving care at the ISS clinic, but who are not enrolled in the safer conception program.
  4. To assess periconception HIV transmission incidence among HIV-affected individuals and couples where the male partner is living with HIV and engaged in the safer conception intervention; Hypothesis 4: Among HIV-affected individuals and couples successfully engaged in the safer conception intervention, investigators hypothesize no (within-couple) cases of periconception-related HIV transmission.
  5. To assess pregnancy and HIV incidence and outcomes among female partners of men living with HIV engaged in the intervention. Hypothesis 5: Of pregnancies ending in live birth, investigators hypothesize <2% incidence of perinatal HIV transmission among infants born to couples successfully engaged in the intervention.
  6. To explore the acceptability and barriers/facilitators of the safer conception intervention among a sub-set of men living with HIV and their HIV sero-different partners.

Hypothesis 6: This is qualitative objective without pre-specified hypotheses.

This study will be conducted at the ISS Clinic in the Mbarara Regional Referral Hospital (MRRH) in Mbarara, Uganda.

This mixed-methods prospective pilot research study includes electronic chart review data, longitudinal survey data (from the male index and female partner participant), and qualitative data from in-depth semi-structured interviews. All of the study efforts will be conducted via the Immune Suppression Syndrome (ISS) Clinic in the Mbarara Regional Referral Hospital in Mbarara, Uganda. The ISS clinic is an IeDEA networks site with a high-quality clinical database. In December 2016, the ISS clinic initiated a safer conception program called the Healthy Families program, which provides counselling and clinical care for HIV-affected individuals and couples who desire pregnancy.

The target population for the Getting to Zero study is men living with HIV with HIV sero-different partners (defined as partners who are HIV-negative or HIV status unknown), who report personal and/or partner pregnancy desire in the next year. Participants will be recruited via information sessions held at the Healthy Families program as well as at the ISS Clinic, MRRH HIV counselling and testing sites, referrals from regional healthcare providers, and via community outreach efforts.

This pilot study aimed at demonstrating proof-of-concept aims to enroll 50 index participants and all female partners. Investigators anticipate, however, enrolling 25 female partners.

The target population for the Getting to Zero study is men living with HIV with HIV sero-different partners (defined as partners who are HIV-negative or HIV status unknown), who report personal and/or partner pregnancy desire in the next year. Participants will be recruited via information sessions held at the Healthy Families program as well as at the ISS Clinic, MRRH HIV counselling and testing sites, referrals from regional healthcare providers, and via community outreach efforts. After providing informed consent, participants will be asked to complete an interviewer-administered questionnaire detailing use of HIV prevention strategies as well as socio-demographic information, partnership dynamics, pregnancy intentions and desires, sexual and reproductive behaviours and history, HIV medical history, mental health, experiences of violence, HIV-related stigma, and social support.

Following the questionnaire, the participant (and his partner if she is present) will be offered safer conception services at the Healthy Families clinic, which includes an up to 30-minute counseling session. Counseling sessions incorporate education and some problem-solving support to help individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive. In addition, (1) all female partners are offered beta hcg pregnancy testing; (2) all HIV-negative participants are offered HIV counselling and testing; (3) all participants will complete testing for STIs (Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis) via GeneXpert. Index participants will also complete testing for syphilis using Bioline testing (treponeme specific) followed by RPR confirmatory testing (non-treponeme specific); and (4) all participants living with HIV will also complete laboratory testing to assess HIV-RNA suppression.

Participants will be offered the safer conception counselling and clinical services at enrollment, 3-months (3M), and 6-months (6M), with two exceptions. First, STI testing will only be offered at the baseline visit for male participants only and subsequent follow-up visits will employ syndromic STI management, which is standard of care at the Healthy Families program. Second, participants will complete HIV-RNA suppression testing at enrolment and 6M.

Male participants will be asked for their consent for the study team to contact their female partners to assess eligibility, interest, and willingness to participate in the study. If he consents for the study team to contact his partner, he will be given an information letter to give to her describing the study purpose and procedures. Once consented, partners will be invited to safe conception counselling sessions as well as to participate in an individual in-depth interview to explore acceptability and barriers/facilitators of the Healthy Families program.

At enrollment and all Healthy Families program follow-up visits (3M and 6M):

  1. all female partners will be offered pregnancy testing via urine beta hcg testing. Results will be available within 3-5 minutes of testing. Women who test positive for pregnancy will be referred to appropriate antenatal care.
  2. all participants who are not known to be HIV-positive will be offered HIV counselling and testing. Individuals confirmed HIV-positive will receive post-test counselling and be referred for appropriate HIV care.
  3. all male participants will undergo objective STI testing at enrollment with same-day pathogen-specific treatment provided for the tested individual as well as to partners. Testing for Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis will be done via GeneXpert. Participants will also complete testing for syphilis using Bioline testing (treponeme specific) followed by RPR confirmatory testing (non-treponeme specific). Symptomatic male patients will be treated as per national STI syndromic management guidelines. Male participants will be given the same course of treatment to take home to their female partners.
  4. all participants living with HIV will also complete laboratory testing to assess HIV-RNA suppression at baseline and 6M.

The procedures described are consistent with usual clinical management of HIV-affected individuals/couples receiving care at the Healthy Families Clinic (i.e., are part of usual clinical management).

Conditions
HIV Infections
Being tested
Safer conception strategies
Medical subject headings
HIV Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Safer conception strategiesOther

    Individuals and couples adopt safer conception strategies including HIV-serostatus disclosure to partner, ART uptake and adherence and HIV-RNA suppression, STI testing and treatment, timing condomless sex to peak fertility, partner ARV use (ART if living with HIV, PrEP if HIV negative), and contraception until ready to conceive.

Study groups in NCT03895619
Study groupRoleWhat they receive
Men living with HIVExperimentalUptake of safer conception strategies among men living with HIV and/or their female partners
Receives: Other: Safer conception strategies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number of HIV infected men and their female partners attending Safer Conception Counselling Sessions and choosing a safer conception strategy that meets their needs

    We will document the number of participants who return to their clinic with their female pregnancy partner to attend Safer Conception Counselling. We will also document the type of strategy chosen.

    Measured: 1.5 year

Secondary outcomes (5)
  1. Types of factors contributing to uptake of safer conception strategies among men living with HIV

    The reasons why men chose to use safer conception strategies will be better understood using unadjusted and adjusted logistic regression models (with 95% confidence intervals)

    Measured: 1.5 year

  2. Number of men living with HIV retained in care who are part of the safer conception intervention.

    Will use Kaplan-Meier methods to measure time to index loss from care

    Measured: 1.5 year

  3. HIV transmission incidence among HIV-affected individuals and couples where the male partner is living with HIV and engaged in the safer conception intervention.

    Will use Kaplan-Meier methods to measure partner HIV-seroconversion.

    Measured: 1.5 year

  4. Periconception HIV transmission incidence among HIV-affected individuals and couples.

    Cumulative incidence of pregnancy will be calculated as the total number of pregnancies over the follow-up period by person-years of follow-up.

    Measured: 1.5 year

  5. HIV incidence among female partners of men living with HIV engaged in the safer conception intervention.

    Will analyze interview data using content analysis.

    Measured: 1.5 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted29 Mar 2019
  2. Study start26 Nov 2018
  3. Primary completion26 Sep 2019
  4. Study completion31 Oct 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Model description
Proof of Concept Research
Masking
None (open label)
Enrolment
47 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03895619
Sponsor's protocol ID
2018s0272
Acronym
G2Z
Status last verified
Apr 2020
First submitted
29 Oct 2018
Last updated
17 Apr 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Safer conception strategies in people with HIV Infections, run by Simon Fraser University at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 14 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number of HIV infected men and their female partners attending Safer Conception Counselling Sessions and choosing a safer conception strategy that meets their needs (time frame: 1.5 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2020.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in